Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | DAO | P14920 | 5/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PNP | P00491 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5199231 | 0.77 | ALDH1A1 (0.47) | SMN1; SMN2DAOLMNAKDM4EMAPT | |
| SCHEMBL9045170 | 0.76 | SMN1; SMN2 (0.48) | SMN1; SMN2DAOARPDE3BPDE3A | |
| SCHEMBL5178271 | 0.76 | ALDH1A1 (0.50) | SMN1; SMN2 | |
| SCHEMBL7101509 | 0.68 | HSPA5 (0.73) | SMN1; SMN2LMNAMAPT | |
| SCHEMBL15844018 | 0.68 | DAO (0.54) | SMN1; SMN2DAOARPDE3BPDE3A | |
| SCHEMBL2673325 | 0.68 | TYMP (0.66) | SMN1; SMN2DAOARPDE3BPDE3A | |
| SCHEMBL10891475 | 0.68 | SHBG (0.49) | KDM4EMAPTPOLB | |
| SCHEMBL14719356 | 0.67 | AR (0.54) | SMN1; SMN2DAOARPDE3BPDE3A | |
| SCHEMBL6472996 | 0.67 | DAO (0.52) | DAOPDE3BPDE3ALMNAKDM4E | |
| SCHEMBL29519238 | 0.66 | IDO1 (0.62) | DAOLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973060-B2 | Fab I inhibitor and process for preparing same | CRYSTALGENOMICS, INC. (KR) | 2011-07-05 | — | — | US | disclosed |
| US-20070135465-A1 | Fab I Inhibitor and Process for Preparing Same | CRYSTALGENOMICS, INC. (KR) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135465-A1 | Fab I Inhibitor and Process for Preparing Same | TFPI, TFPI2, FCGRT | SMN1; SMN2 4359/4885DAO 3085/4885AR 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.